NABAT MIRPOURIAN: Open Payments
NPI 1447342704 · OCEANSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$262 in 14 payments from 8 companies in 2025. Trend: 2023 $549 · 2024 $678 · 2025 $262
Food & beverage: $262
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $86 |
| CVRx, Inc. | 3 | $56 |
| Novartis Pharmaceuticals Corporation | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $18 |
| Janssen Biotech, Inc. | 1 | $17 |
| Amgen Inc. | 1 | $14 |
| SCPHARMACEUTICALS INC. | 1 | $14 |
Products named: JARDIANCE, Barostim Neo System, LEQVIO, AMVUTTRA, Kerendia, TREMFYA, REPATHA, FUROSCIX.
Industry payments across CA — which companies pay providers there.
